Evidence map›Paper›PMID 38039275›Full record

ReviewPLoS neglected tropical diseases2023

Ensuring access to essential health products: Lessons from Colombia's leishmaniasis control and elimination initiative.

Carol Vlassoff, Nora Giron, Mauricio Javier Vera Soto, Ana Nilce Silveira Maia-Elkhoury, Arush Lal, Luis Gerardo Castellanos, Gisele Almeida, Christopher Lim

Open access · goldAbstract readReview
In one paragraph

Review in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Carol VlassoffSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.ORCID 0000-0003-1362-4034
Nora GironStrategic Fund, Pan American Health Organization, Washington, DC, United States of America.
Mauricio Javier Vera SotoSubdireccion de enfermedades transmisibles, Ministerio de Salud y Protección Social, Bogotá, Colombia.
Ana Nilce Silveira Maia-ElkhouryNeglected, Tropical and Vector-Borne Diseases Unit, Pan American Health Organization, Rio de Janeiro, Brazil.
Arush LalStrategic Fund, Pan American Health Organization, Washington, DC, United States of America.
Luis Gerardo CastellanosNeglected, Tropical and Vector-Borne Diseases Unit, Pan American Health Organization, Washington, DC, United States of America.
Gisele AlmeidaDepartment of Health Systems and Services, Pan American Health Organization, Washington, DC, United States of America.ORCID 0000-0001-7880-6993
Christopher LimStrategic Fund, Pan American Health Organization, Washington, DC, United States of America.ORCID 0009-0001-9543-6258
World Health Organization Regional Office for the Americas · USMinistry of Health and Social Protection · COPan American Health Organization (Brasil) · BRUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis paper identifies opportunities and challenges for leishmaniasis control and elimination in Colombia, emphasizing the role of pooled procurement of essential medicines and supplies. Colombia is among the countries most affected by leishmaniasis globally, and also faces the dual challenge of procuring critically needed medicines in the context of limited national resources. It recently renewed its commitment to the control and elimination of leishmaniasis under its 2022-2031 Public Health Plan (PDSP) through a comprehensive public health approach. METHODOLOGY/PRINCIPAL

findingsThe methodology comprises a comprehensive literature review and key informant interviews with leishmaniasis experts from the Colombian national control program and PAHO/WHO, focusing on cutaneous, mucocutaneous, and visceral leishmaniasis. Leishmaniasis is endemic throughout Colombia, with over 11 million people at risk, many of whom live in poverty-stricken, remote and isolated rural areas with limited access to health services. Leishmaniasis care, including medicines, is provided free of charge, but many barriers were nonetheless identified at environmental, population, and health system levels, including the supply of quality-assured medicines. Opportunities to alleviate these barriers were identified, including the support of the PAHO Strategic Fund. Within the context of the sustainable development goals and international leishmaniasis control and elimination targets, Colombian officials have established their own priorities, the highest of which is the reduction of deaths from visceral leishmaniasis. CONCLUSIONS/SIGNIFICANCE: The elimination of leishmaniasis as a public health problem presents significant challenges, given its biological complexity and diversity, physical and clinical manifestations, social and economic impacts, frequently burdensome treatment regimens, and insufficient supply of necessary medicines. However, rigorous prevention and control efforts through strong political commitment and a highly motivated workforce can dramatically reduce its burden. Colombia's new PDSP, which highlights leishmaniasis control, is an opportunity for a revitalized health system response through committed leadership, intersectoral actions, and partnerships with international organizations that share a common vision.

Indexed as

LeishmaniasisLeishmaniasis, VisceralColombiaHumansPovertySustainable Development

Identifiers

PMID38039275
PMCPMC10691678
OpenAlexW4389235789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.